Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice

Feng Zhang; Zhinan Chen; Dan Wu; Le Tian; Qing Chen; Yuqing Ye; Wei Chen; Xiaoxing Wu; Peng Wu; Weilan Yuan; Yan Qiu; Zhiguang Zhou; Zhiqiang Du; Fang Hu

iScience (Dec 2021)

Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice

Feng Zhang,
Zhinan Chen,
Dan Wu,
Le Tian,
Qing Chen,
Yuqing Ye,
Wei Chen,
Xiaoxing Wu,
Peng Wu,
Weilan Yuan,
Yan Qiu,
Zhiguang Zhou,
Zhiqiang Du,
Fang Hu

Affiliations

Feng Zhang: National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education，Metabolic Syndrome Research Center, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan, China
Zhinan Chen: National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education，Metabolic Syndrome Research Center, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan, China
Dan Wu: National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education，Metabolic Syndrome Research Center, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan, China
Le Tian: National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education，Metabolic Syndrome Research Center, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan, China
Qing Chen: National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education，Metabolic Syndrome Research Center, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan, China
Yuqing Ye: National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education，Metabolic Syndrome Research Center, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan, China
Wei Chen: National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education，Metabolic Syndrome Research Center, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan, China
Xiaoxing Wu: Innovation Center, Shanghai Benemae Pharmaceutical Corporation, 916 Ziping Road, PuDong, Shanghai, China
Peng Wu: Innovation Center, Shanghai Benemae Pharmaceutical Corporation, 916 Ziping Road, PuDong, Shanghai, China
Weilan Yuan: Innovation Center, Shanghai Benemae Pharmaceutical Corporation, 916 Ziping Road, PuDong, Shanghai, China
Yan Qiu: Innovation Center, Shanghai Benemae Pharmaceutical Corporation, 916 Ziping Road, PuDong, Shanghai, China
Zhiguang Zhou: National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education，Metabolic Syndrome Research Center, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan, China
Zhiqiang Du: Innovation Center, Shanghai Benemae Pharmaceutical Corporation, 916 Ziping Road, PuDong, Shanghai, China; Corresponding author
Fang Hu: National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education，Metabolic Syndrome Research Center, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan, China; Corresponding author

Journal volume & issue: Vol. 24, no. 12
p. 103382

Abstract

Read online

Summary: GLP-1 analogs are a class of glucose-lowering agents with multiple benefits in diabetes, but its role in adipose tissues remains to be elucidated. The aim of this study was to determine the action of recombinant human GLP-1 (rhGLP-1) Beinaglutide (BN) in the insulin sensitivity and lipid metabolism of adipose tissues. We have shown that, after BN injection, obese mice displayed lower body weight, fat mass, and plasma lipid levels. In addition, BN promoted the insulin sensitivity in the white adipose tissues. Furthermore, we have found that the BN treatment caused significant changes in content and composition of different lipid classes, including glycerolipids, glycerophospholipids, and sphingolipids, as well as expression of genes in lipid metabolic pathways in the adipose tissues. Taken together, our data demonstrate that BN could resist HFD-induced obesity by targeting the composition of major lipid classes and the expression of genes in lipid metabolism of adipose tissues.

Published in iScience

ISSN: 2589-0042 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science
Website: http://www.cell.com/iscience/home

About the journal

Abstract

Keywords